HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial.

Quchang OuyangYing WangJian ZhangQiong WuHongying WeiChuan LiXiaoling QianXi-Chun Hu

Published in: Cancer medicine (2023)

HS-10352 at 6 mg QD was well-tolerated in patients with HR-positive, HER2-negative ABC, and showed preliminary antitumor activity in patients with PIK3CA mutated tumors. These findings support the further clinical development of HS-10352.

Keyphrases

clinical trial
study protocol
phase iii
open label
phase ii
young adults